Small Molecules

02 Dec 2021 Accutar Biotechnology Announces First Patient Dosed with AC0682 in Phase 1 Study in Patients with ER-Positive / HER2-Negative Locally Advanced or Metastatic Breast Cancer
02 Dec 2021 Amgen Announces Positive Top-Line Results From Otezla® (apremilast) Phase 3 DISCREET Study In Moderate To Severe Genital Psoriasis
02 Dec 2021 Vertex Announces Positive Results From Phase 2 Study of VX-147 in APOL1-Mediated Focal Segmental Glomerulosclerosis
02 Dec 2021 Sage Therapeutics and Biogen Announce Positive, One-Year Zuranolone 50 mg Data in the Ongoing Open-Label SHORELINE Study in Patients with MDD
01 Dec 2021 Insilico Medicine Initiates First-in-Human Study of ISM001-055, a Novel Drug Discovered Using Insilico's Proprietary End-to-end Artificial Intelligence Platform
30 Nov 2021 Kymera Therapeutics Announces FDA Clearance of Investigational New Drug Application (IND) for IRAKIMiD Degrader, KT-413
30 Nov 2021 FDA Approves New Imaging Drug to Help Identify Ovarian Cancer Lesions
30 Nov 2021 Treadwell Therapeutics Announces US FDA Clearance of IND Application for Phase 2 Study of TTK inhibitor, CFI-402257
30 Nov 2021 Bristol Myers Squibb’s Applications for Deucravacitinib for the Treatment of Moderate to Severe Plaque Psoriasis Accepted by U.S. Food and Drug Administration and Validated by European Medicines Agency
30 Nov 2021 LYNPARZA® (olaparib) Granted Priority Review in the US for BRCA-Mutated HER2-Negative High-Risk Early Breast Cancer
30 Nov 2021 Seres Therapeutics Announces First Patient Enrolled in Phase 1b Study of SER-155, an Investigational Microbiome Therapeutic to Reduce the Risk of Antibiotic-Resistant Bacterial Infections and Graft-Versus-Host Disease (GvHD)
30 Nov 2021 NiKang Therapeutics and Pfizer Enter Clinical Trial Collaboration and Supply Agreement to Evaluate Novel Combination Therapies for the Treatment of Advanced Clear Cell Renal Cell Carcinoma
30 Nov 2021 Blade Therapeutics Announces Positive Topline Data from Phase 1 Clinical Study of Cudetaxestat, a Non-Competitive Autotaxin Inhibitor in Clinical Development for Idiopathic Pulmonary Fibrosis
29 Nov 2021 European Commission Approves LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) for Patients With Certain Types of Endometrial Carcinoma
29 Nov 2021 European Commission Approves LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) as First-Line Treatment for Adult Patients With Advanced Renal Cell Carcinoma
26 Nov 2021 Merck and Ridgeback Biotherapeutics Provide Update on Results from MOVe-OUT Study of Molnupiravir, an Investigational Oral Antiviral Medicine, in At Risk Adults With Mild-to-Moderate COVID-19
25 Nov 2021 Kintor Pharma Receives IND Clearance by NMPA for KX-826's Pivotal Study to Treat Male Alopecia Patients
25 Nov 2021 Kura Oncology Provides Update on Phase 1b Study of KO-539 in Acute Myeloid Leukemia
24 Nov 2021 Bristol Myers Squibb Receives European Commission Approval of Zeposia (ozanimod) for use in Adults with Moderately to Severely Active Ulcerative Colitis
24 Nov 2021 BeiGene Announces Approval of BRUKINSA (zanubrutinib) in the European Union for Treatment of Adults with Waldenström’s Macroglobulinemia
24 Nov 2021 Takeda’s LIVTENCITY (maribavir) Approved by FDA for Post-Transplant CMV Refractory to Conventional Antiviral Therapies
23 Nov 2021 Aadi Bioscience Announces FDA Approval of its First Product FYARRO™ for Patients with Locally Advanced Unresectable or Metastatic Malignant Perivascular Epithelioid Cell Tumor (PEComa)
22 Nov 2021 Deciphera Receives European Commission Approval of QINLOCK® for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
22 Nov 2021 BeiGene Initiates First-in-Human Phase 1 Clinical Trial of Investigational TYK2 Inhibitor BGB-23339
21 Nov 2021 European Commission approves Roche’s Gavreto (pralsetinib) for the treatment of adults with RET fusion-positive advanced non-small cell lung cancer

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2020 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up